- Home
- PRT vs RNXT Comparison
PRT vs RNXT Comparison
Compare PRT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | RNXT |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 37.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRT | RNXT |
|---|---|---|
| Price | $2.95 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 52.3K | ★ 479.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 12.70% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $267.59 |
| Revenue Next Year | N/A | $307.07 |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $2.61 | $0.70 |
| 52 Week High | $4.28 | $1.45 |
Technical Indicators
Market Signals| Indicator | PRT | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 54.42 |
| Support Level | N/A | $0.80 |
| Resistance Level | $3.57 | $1.07 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.41 | 37.78 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.